Skip to content

Trial Summary

An Open Label, Randomised Phase 2 Study to Evaluate the Safety and Efficacy of MTL CEBPA Administered in Combination with Sorafenib or Sorafenib Alone, in TKI Naive participants with Previously Treated Advanced Hepatocellular Carcinoma (HCC) and Hepatitis B or Hepatitis C Virus (OUTREACH2)

Acronym:

OUTREACH2

ACTRN/NCT /ethics:

NCT04710641

Scientific title:

Radomised Phase II Study of MTL-CEBPA Plus Sorafenib or Sorafenib Alone (OUTREACH2)

Sponsor / Cooperative group:

Mina Alpha Limited

Trial & Patient Characteristics

Cancer TypeOther
Trial TypeTreatment
PhasePhase II
Age Range18 years and older
SexAll
Tumour Stream Liver
Cancer StageLocally Advanced
Anticipated Start Date2022-01-01
Anticipated End Date2025-05-01

Participating Hospitals

HospitalThe Queen Elizabeth Hospital
Clinical Trial CoordinatorStella Papacharissiou
Emailstella.papacharissiou@sa.gov.au
Phone08 8222 6140
Principal InvestigatorDr Vy Broadbridge
Recruitment StatusNot Yet Recruiting